3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
155
Leukemia, Lymphocytic, Chronic, B-Cell
43
Lymphoma, Large B-Cell, Diffuse
26
Lymphoma
25
Lymphoma, Non-Hodgkin
23
Lymphoma, Mantle-Cell
23
Lymphoma, Follicular
23
Leukemia
22
Recurrence
21
Neoplasms, Plasma Cell
19
Myelodysplastic Syndromes
12
Lymphoma, B-Cell, Marginal Zone
12
Leukemia, Myeloid, Acute
12
Waldenstrom Macroglobulinemia
8
Smoldering Multiple Myeloma
8
Hodgkin Disease
8
Prostatic Neoplasms
7
Lymphoma, B-Cell
6
Lymphoma, T-Cell
5
Lymphoma, Large-Cell, Anaplastic
5
Hematologic Diseases
5
Sezary Syndrome
4
Mycosis Fungoides
4
Lymphoma, T-Cell, Peripheral
4
Leukemia, Myelomonocytic, Chronic
4
Immunoblastic Lymphadenopathy
4
Anemia
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Polycythemia Vera
3
Lymphoma, T-Cell, Cutaneous
3
Interventions
blinatumomab
5
Rituximab
4
Cyclophosphamide
4
Brentuximab Vedotin
3
ponatinib
2
Vincristine
2
Prednisone
2
Etoposide
2
Doxorubicin
2
tetulomab tetraxetan lu-177
1
pembrolizumab
1
ibrutinib
1
ibritumomab tiuxetan
1
fludarabine
1
durvalumab
1
denileukin diftitox
1
cobomarsen
1
Vorinostat
1
Melphalan
1
Lutetium
1
Lenalidomide
1
Imatinib Mesylate
1
Ifosfamide
1
Everolimus
1
Cytarabine
1
Carmustine
1
Carboplatin
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphatic Diseases
×
Lenalidomide
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts